These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 28974512)

  • 1. Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis.
    Leclerc J; Blais C; Rochette L; Hamel D; Guénette L; Poirier P
    Circ Cardiovasc Qual Outcomes; 2017 Oct; 10(10):. PubMed ID: 28974512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Did Generic Clopidogrel Commercialization Affect Trends of ER Consultations and Hospitalizations in the Population Treated with Clopidogrel?
    Leclerc J; Blais C; Rochette L; Hamel D; Guénette L; Poirier P
    Drugs Aging; 2019 Aug; 36(8):759-768. PubMed ID: 31073846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public Health Outcomes May Differ After Switching from Brand-Name to Generic Angiotensin II Receptor Blockers.
    Leclerc J; Blais C; Rochette L; Hamel D; Guénette L; Beaudoin C; Poirier P
    Drugs R D; 2020 Jun; 20(2):135-145. PubMed ID: 32342284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in Hospital Visits for Generic and Brand-Name Warfarin Users in Québec, Canada: A Population-Based Time Series Analysis.
    Leclerc J; Blais C; Rochette L; Hamel D; Guénette L; Poirier P
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):287-297. PubMed ID: 30471054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis.
    Grosso AM; Bodalia PN; Macallister RJ; Hingorani AD; Moon JC; Scott MA
    Int J Clin Pract; 2011 Mar; 65(3):253-63. PubMed ID: 21284790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries.
    Godman B; Wettermark B; Miranda J; Bennie M; Martin A; Malmström RE
    Int J Clin Pract; 2013 Sep; 67(9):853-62. PubMed ID: 23560825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.
    Lin JW; Chang CH; Caffrey JL; Wu LC; Lai MS
    Hypertension; 2014 May; 63(5):968-76. PubMed ID: 24516110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on.
    Usher-Smith J; Ramsbottom T; Pearmain H; Kirby M
    Int J Clin Pract; 2008 Mar; 62(3):480-4. PubMed ID: 18201178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switch strategies in the management of hypertension: a cost minimisation analysis of angiotensin receptor blocker based regimen.
    Belsey JD
    Curr Med Res Opin; 2008 Feb; 24(2):581-9. PubMed ID: 18198012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of valsartan versus losartan and the effect of switching.
    Baker TM; Goh J; Johnston A; Falvey H; Brede Y; Brown RE
    J Med Econ; 2012; 15(2):253-60. PubMed ID: 22084957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful implementation of a P&T-approved therapeutic interchange program of angiotensin II receptor blockers in a medical center in Taiwan.
    Lee YY; Hsiao P; Lin YM; Yen YH; Chen HY
    Value Health; 2012; 15(1 Suppl):S111-5. PubMed ID: 22265056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries.
    Hesse U; Godman B; Petzold M; Martin A; Malmström RE
    Appl Health Econ Health Policy; 2013 Dec; 11(6):677-85. PubMed ID: 24105097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension.
    Zhenfeng Zheng ; Huilan Shi ; Junya Jia ; Dong Li ; Shan Lin
    J Renin Angiotensin Aldosterone Syst; 2011 Sep; 12(3):365-74. PubMed ID: 21421652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
    Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
    Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential Medicare Savings From Generic Substitution and Therapeutic Interchange of ACE Inhibitors and Angiotensin-II-Receptor Blockers.
    Growdon ME; Sacks CA; Kesselheim AS; Avorn J
    JAMA Intern Med; 2019 Dec; 179(12):1712-1714. PubMed ID: 31380893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Choice of angiotensin receptor blocker in moderate hypertension. A UK-based cost-benefit comparison of olmesartan- and candesartan-based regimens.
    Belsey JD
    J Med Econ; 2011; 14(5):553-61. PubMed ID: 21707445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving Adherence to Treatment and Reducing Economic Costs of Hypertension: The Role of Olmesartan-Based Treatment.
    Costa FV
    High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):265-274. PubMed ID: 28695464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II receptor blockers for the treatment of heart failure: a class effect?
    Hudson M; Humphries K; Tu JV; Behlouli H; Sheppard R; Pilote L
    Pharmacotherapy; 2007 Apr; 27(4):526-34. PubMed ID: 17381379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-care costs of losartan and candesartan in the primary treatment of hypertension.
    Henriksson M; Russell D; Bodegard J; Kjeldsen S; Hasvold P; Stålhammar J; Levin LÅ
    J Hum Hypertens; 2011 Feb; 25(2):130-6. PubMed ID: 20376078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.